The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 10, 2020
Filed:
Oct. 27, 2015
Applicant:
Fred Hutchinson Cancer Research Center, Seattle, WA (US);
Inventors:
Susanna Carolina Berger, Seattle, WA (US);
Stanley R. Riddell, Sammamish, WA (US);
Assignee:
Fred Hutchinson Cancer Research Center, Seattle, WA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/00 (2006.01); C07K 14/725 (2006.01); A61K 39/12 (2006.01); A61K 35/17 (2015.01); A61K 35/15 (2015.01); A61K 45/06 (2006.01); C07K 14/705 (2006.01); C07K 16/30 (2006.01); C07K 16/28 (2006.01); A61K 48/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/0011 (2013.01); A61K 35/15 (2013.01); A61K 35/17 (2013.01); A61K 39/00111 (2018.08); A61K 39/00117 (2018.08); A61K 39/001103 (2018.08); A61K 39/001104 (2018.08); A61K 39/001106 (2018.08); A61K 39/001112 (2018.08); A61K 39/001113 (2018.08); A61K 39/001117 (2018.08); A61K 39/001122 (2018.08); A61K 39/001124 (2018.08); A61K 39/001129 (2018.08); A61K 39/001153 (2018.08); A61K 39/001156 (2018.08); A61K 39/001157 (2018.08); A61K 39/001168 (2018.08); A61K 39/001171 (2018.08); A61K 39/001181 (2018.08); A61K 39/001182 (2018.08); A61K 39/001186 (2018.08); A61K 39/001188 (2018.08); A61K 39/001195 (2018.08); A61K 39/12 (2013.01); A61K 45/06 (2013.01); C07K 14/7051 (2013.01); C07K 14/70578 (2013.01); C07K 16/30 (2013.01); A61K 48/00 (2013.01); A61K 2039/505 (2013.01); A61K 2039/5156 (2013.01); A61K 2039/5158 (2013.01); A61K 2039/54 (2013.01); A61K 2039/545 (2013.01); A61K 2039/55522 (2013.01); A61K 2039/57 (2013.01); C07K 16/2803 (2013.01); C07K 2317/622 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C07K 2319/33 (2013.01);
Abstract
The present disclosure provides compositions and methods for boosting, augmenting or enhancing the efficacy of the adoptive cellular immunotherapy by using modified T cells expressing an antigen binding protein in conjunction with modified cells (such as hematopoietic progenitor cells, modified human immune system cells or a combination thereof) expressing the antigen specifically bound by the antigen binding protein of the modified T cells.